Farah Champsi Sells 20,450 Shares of Kite Pharma, Inc. (KITE) Stock

Kite Pharma, Inc. (NASDAQ:KITE) Director Farah Champsi sold 20,450 shares of the company’s stock in a transaction that occurred on Friday, June 16th. The stock was sold at an average price of $89.79, for a total transaction of $1,836,205.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Farah Champsi also recently made the following trade(s):

  • On Friday, April 28th, Farah Champsi sold 19,168 shares of Kite Pharma stock. The stock was sold at an average price of $82.75, for a total transaction of $1,586,152.00.
  • On Tuesday, April 25th, Farah Champsi sold 46,783 shares of Kite Pharma stock. The stock was sold at an average price of $82.80, for a total transaction of $3,873,632.40.
  • On Monday, April 24th, Farah Champsi sold 25,818 shares of Kite Pharma stock. The stock was sold at an average price of $82.34, for a total transaction of $2,125,854.12.
  • On Wednesday, April 26th, Farah Champsi sold 123,913 shares of Kite Pharma stock. The stock was sold at an average price of $82.67, for a total transaction of $10,243,887.71.
  • On Monday, April 17th, Farah Champsi sold 115,376 shares of Kite Pharma stock. The stock was sold at an average price of $82.42, for a total transaction of $9,509,289.92.

Kite Pharma, Inc. (KITE) opened at 89.29 on Tuesday. Kite Pharma, Inc. has a 52-week low of $39.82 and a 52-week high of $91.76. The firm’s 50-day moving average is $78.25 and its 200-day moving average is $66.56. The stock’s market capitalization is $5.05 billion.

Kite Pharma (NASDAQ:KITE) last issued its quarterly earnings results on Monday, May 8th. The biopharmaceutical company reported ($1.74) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.68) by $0.06. The company had revenue of $9.80 million during the quarter, compared to the consensus estimate of $8.85 million. Kite Pharma had a negative net margin of 1,166.54% and a negative return on equity of 55.80%. The company’s quarterly revenue was up 92.2% on a year-over-year basis. During the same quarter last year, the firm posted ($0.60) earnings per share. Analysts predict that Kite Pharma, Inc. will post ($8.05) earnings per share for the current year.

Insider Buying and Selling by Quarter for Kite Pharma (NASDAQ:KITE)

ILLEGAL ACTIVITY WARNING: “Farah Champsi Sells 20,450 Shares of Kite Pharma, Inc. (KITE) Stock” was first reported by Ticker Report and is the sole property of of Ticker Report. If you are reading this story on another publication, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright law. The correct version of this story can be viewed at https://www.tickerreport.com/banking-finance/2654879/farah-champsi-sells-20450-shares-of-kite-pharma-inc-kite-stock.html.

Hedge funds and other institutional investors have recently made changes to their positions in the company. TD Asset Management Inc. increased its position in shares of Kite Pharma by 148.7% in the first quarter. TD Asset Management Inc. now owns 61,550 shares of the biopharmaceutical company’s stock valued at $4,831,000 after buying an additional 36,800 shares during the period. Russell Investments Group Ltd. acquired a new stake in shares of Kite Pharma during the fourth quarter valued at $801,000. State Board of Administration of Florida Retirement System boosted its stake in shares of Kite Pharma by 0.9% in the fourth quarter. State Board of Administration of Florida Retirement System now owns 21,963 shares of the biopharmaceutical company’s stock valued at $985,000 after buying an additional 200 shares in the last quarter. Hudson Bay Capital Management LP boosted its stake in shares of Kite Pharma by 61.8% in the fourth quarter. Hudson Bay Capital Management LP now owns 122,626 shares of the biopharmaceutical company’s stock valued at $5,499,000 after buying an additional 46,840 shares in the last quarter. Finally, UBS Asset Management Americas Inc. boosted its stake in shares of Kite Pharma by 2.9% in the fourth quarter. UBS Asset Management Americas Inc. now owns 404,137 shares of the biopharmaceutical company’s stock valued at $18,122,000 after buying an additional 11,291 shares in the last quarter. Institutional investors own 85.33% of the company’s stock.

KITE has been the subject of a number of research reports. Canaccord Genuity set a $90.00 target price on shares of Kite Pharma and gave the stock a “buy” rating in a research report on Tuesday, June 6th. Roth Capital restated a “buy” rating and set a $93.00 target price on shares of Kite Pharma in a research report on Thursday, April 6th. Cowen and Company restated a “buy” rating on shares of Kite Pharma in a research report on Wednesday, June 7th. Zacks Investment Research upgraded shares of Kite Pharma from a “sell” rating to a “hold” rating in a research report on Thursday, March 2nd. Finally, FBR & Co restated a “buy” rating on shares of Kite Pharma in a research report on Tuesday, May 30th. One research analyst has rated the stock with a sell rating, seven have assigned a hold rating, twelve have issued a buy rating and one has issued a strong buy rating to the company. Kite Pharma has an average rating of “Buy” and an average price target of $83.13.

About Kite Pharma

Kite Pharma, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cancer immunotherapy products to target and kill cancer cells. The Company offers engineered autologous cell therapy, which is an approach to the treatment of cancer. Its therapy involves modifying a patient’s T cells outside the patient’s body, or ex vivo, causing the T cells to express chimeric antigen receptors (CARs), or T cell receptors (TCRs), and then reinfusing the engineered T cells back into the patient.new TradingView.widget({ “height”: 400, “width”: 625, “symbol”: “NASDAQ:KITE”, “interval”: “D”, “timezone”: “Etc/UTC”, “theme”: “White”, “style”: “1”, “locale”: “en”, “toolbar_bg”: “#f1f3f6”, “enable_publishing”: false, “hideideas”: true, “referral_id”: “2588”});

Receive News & Ratings for Kite Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kite Pharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
President Trump Hurting Tourism in the U.S.
President Trump Hurting Tourism in the U.S.
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Blue Apron Filed Thursday for Public Offering
Blue Apron Filed Thursday for Public Offering
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Large Auto Lender Checked Just 8% of Incomes for Applicants
Large Auto Lender Checked Just 8% of Incomes for Applicants


Leave a Reply

© 2006-2017 Ticker Report. Google+.